<DOC>
	<DOCNO>NCT01098006</DOCNO>
	<brief_summary>The purpose study develop characterize immunological assay blood sample .</brief_summary>
	<brief_title>A Study Adult Subjects With Chronic Hepatitis B Infection Support Development Immunological Assays</brief_title>
	<detailed_description>Chronic hepatitis B patient follow 4 group ask participate study : - Group A : Immune tolerant patient - Group B : Hepatitis B envelope antigen ( HBeAg ) -positive chronic hepatitis B patient - Group C : Healthy carrier - Group D : Hepatitis B envelope antigen ( HBeAg ) -negative chronic hepatitis B patient</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<criteria>Written inform consent obtain subject . Subjects investigator believe comply requirement protocol . A male female , include , 18 65 year age study start . Evidence chronic hepatitis B infection per medical record . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject practice adequate contraception 30 day prior study start . In addition general inclusion criterion , subject satisfy ALL specific criterion accord specify group maximum 6 month prior Visit 1 per medical record : Group A : Immune tolerant patient Viral load : &gt; 2x107 IU/mL HBV DNA HBeAg positive Normal level ALT accord lab range Group B : HBeAg positive chronic hepatitis B patient Viral load : &gt; 2x104 IU/mL HBV DNA HBeAg positive Increased level ALT and/or evidence chronic hepatitis liver biopsy Group C : Healthy carrier Viral load : exceed 2x103 IU/mL HBV DNA HBeAg negative Normal level ALT measure least twice , least 3 month apart , last 6 month Group D : HBeAg negative chronic hepatitis B patient Viral load : &gt; 2x103 IU/mL HBV DNA HBeAg negative Increased level ALT and/or evidence chronic hepatitis liver biopsy Any hepatitis B specific treatment prior blood sample Visit 1 . Any know clinically significant anaemia condition within 7 day prior study entry ( Visit 1 ) per medical record would preclude draw blood describe protocol . Receipt live attenuate vaccine within 30 day precede blood sample Visit 1 administration pandemic influenza vaccine within 21 day precede blood sample Visit 1 . Receipt blood product within 120 day prior study entry ( Visit 1 ) . Receipt immunoglobulins within 120 day prior study entry ( Visit 1 ) . Receipt interferon within 120 day prior study entry ( Visit 1 ) . Use investigational nonregistered product ( drug vaccine ) within 30 day precede study start , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . History immunosuppressive immunemediated disorder include autoimmune disease , human immunodeficiency virus ( HIV ) infection hepatitis C infection , base medical history physical examination ( laboratory testing require ) . Pregnant lactate female . History malignancy ( unless surgical excision follow sufficient observation period , least 5 year , give reasonable assurance sustain cure , estimate investigator , likely recur study period ) . Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug ( include chloroquine ) within six month prior blood sample Visit 1 ( corticosteroid , mean prednisone â‰¥10 milligram/day ( 10 mg/day ) , equivalent ) . Inhaled topical steroid allow . History type I type II diabetes mellitus include case control diet alone ( subject past gestational diabetes eligible ) . History major congenital defect . Subjects history , current , alcohol substance abuse .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Immunological assay</keyword>
	<keyword>Chronic hepatitis B</keyword>
</DOC>